8月25日，康弘药业获华福证券买入评级，近一个月康弘药业获得2份研报关注。
研报预计2024-2026年公司收入增速分别为20%/15%/14%，归母净利润增速分别为21%/17%/14%。研报认为，公司康柏西普仍然处于快速增长期且公司创新药临床管线丰富具备差异化。
风险提示：产品销售不及预期的风险、行业政策不及预期的风险、药品研发创新、仿制药研发及一致性评价的风险。
- Headlines
- 康弘药业获华福证券买入评级，康柏西普持续高增长，眼科脑科创新药值得期待
康弘药业获华福证券买入评级，康柏西普持续高增长，眼科脑科创新药值得期待
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Hot News
Updated
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.